Johnson and Johnson (NYSE:JNJ) shares are trending on Friday. In the last week, the pharmaceutical company announced positive results from two clinical trials and authorization from Health Canada for RYBREVANT in combination with platinum-based chemotherapy.
The Details: The first of the two clinical trials is a Phase 3 study regarding the use of nipocalimab for patients with generalized myasthenia gravis.
In the first trial, patients who received nipocalimab alongside standard treatment over the course of 24 weeks achieved superiority over the placebo group in activities of daily living. The study ...